Media/Policy Watch

Media/Policy Watch
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. Media Watch is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from Journal Watch above which scans the peer-reviewed journal ecology.
We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.


The Atlantic
Accessed 25 July 2020
[No new, unique, relevant content]


Accessed 25 July 2020
Government invests £100m to ‘scale up’ Covid-19 vaccine at Braintree facility
23 July 2020
The government is investing £100m in a new centre to ensure any successful Covid-19 vaccine can be mass produced in the UK.
It is upgrading an existing facility in Braintree into a state-of-the-art Cell and Gene Therapy Catapult Manufacturing Innovation Centre.
The Department for Business, Energy and Industrial Strategy (BEIS) said it would have the capacity to produce “millions of doses” each month.
It is due to open in December 2021.
The new centre will complement the Vaccines Manufacturing and Innovation Centre (VMIC), under construction in Oxfordshire, which will be able to produce enough vaccine doses to serve the entire UK population.

Coronavirus: Oxford vaccine appears safe and triggers an immune response
20 Jul 2020
The UK government has secured early access to millions of doses of potential Covid-19 vaccines that are being prepared by medical researchers.


The Economist
Accessed 25 July 2020
[No new, unique, relevant content]


Financial Times
Accessed 25 July 2020
Person in the News
Sarah Gilbert, the researcher leading the race to a Covid-19 vaccine
July 24, 2020
…The vaccinology professor at Oxford university’s Jenner Institute had been preparing for just such a momentous event. Her lab had developed technology to create vaccines against virulent viruses. As soon as Chinese scientists published genetic details of the new coronavirus — providing a target for vaccine development — she moved ahead at full speed. This week, Oxford published encouraging results from the first phase of testing of its ChAdOx1 vaccine, showing it generated antibodies and immune cells to recognise and kill the Sars-Cov-2 virus responsible for Covid-19….

Rich country vaccine rush threatens supply security |
July 23, 2020
[See Milestones above for detail]


Accessed 25 July 2020
Jul 20, 2020
Over 100,000 People Volunteered For Covid-19 Vaccine Trial In Less Than Two Weeks
At least 30,000 volunteers are needed for each of the four companies that plan to launch Phase 3 trials in the U.S.
By Daniel Cassady Forbes Staff


Foreign Affairs
Accessed 25 July 2020
[No new, unique, relevant content]


Foreign Policy
Accessed 25 July 2020 | [No new, unique, relevant content]
[No new, unique, relevant content]


The Guardian
Boris Johnson says ‘anti-vaxxers are nuts’ | Society | The Guardian
24 July 2020

Covid-19 kills scores of health workers in war-torn Yemen
23 July 2020


New Yorker
Accessed 25 July 2020
Medical Dispatch
The Long Game of Coronavirus Research
Warp-speed vaccine trials grab our attention, but more deliberate work is just as urgent.
By Jerome Groopman
July 23, 2020


New York Times
Accessed 25 July 2020
Corporate Insiders Pocket $1 Billion in Rush for Coronavirus Vaccine
Well-timed stock bets have generated big profits for senior executives and board members at companies developing vaccines and treatments.
By David Gelles and Jesse Drucker
PRINT EDITION July 26, 2020

Asia Today: Amid New Surge, India Tests Potential Vaccine
India began its first human trials of a novel coronavirus vaccine candidate as the world’s second-most populous country recorded nearly 49,000 new cases.
By The Associated Press July 24

U.S. Panel Charged to Plan Fair Distribution of Eventual COVID-19 Vaccine
U.S. public health officials on Friday charged a group of independent scientists and ethicists with developing guidelines to determine who should get the first doses of a COVID-19 vaccine, once one becomes available.
By Reuters July 24


Human Trials of Second Russian COVID-19 Vaccine to Start July 27-TASS
Human trials of second potential coronavirus vaccine, developed by the Siberian Vector institute, will begin on July 27, the TASS news agency cited Russia’s consumer safety watchdog as saying on Friday.
By Reuters July 24

Exclusive: EU Eyes COVID-19 Vaccines at Less Than $40, Shuns WHO-Led Alliance-Sources
The European Union is not interested in buying potential COVID-19 vaccines through an initiative co-led by the World Health Organisation as it deems it slow and high-cost, two EU sources told Reuters, noting the bloc was in talks with drugmakers for shots cheaper than $40.
By Reuters

Asia Pacific
WHO Scientist Sees Regulators Cooperating to Speed COVID-19 Vaccine Approval
Regulators that normally work within their own countries or regions will likely harmonize efforts on potential COVID-19 vaccines to speed up their approvals once they become available, WHO chief scientist Soumya Swaminathan said on Friday.
By Reuters July 24


Washington Post
Accessed 25 July 2020
Editorial Board – Countries should stop hacking each other and start cooperating on a vaccine
Jul 25, 2020

Dr. Anthony Fauci details the COVID-19 vaccine timeline
Dr. Anthony Fauci says we will likely know if a potential coronavirus vaccine is safe and effective by the end of December of this year. “It is likely that in the beginning of next year we would have tens of millions of doses available…as we get into 2021, several months in, you would have vaccine that would be widely available to people in the United States.”
Washington Post Live · Jul 24, 2020